Generex Biotech Corp

aus meiner Sicht war dies der Grund warum am Freitag der Kurs endlich wieder angestiegen ist.

http://quotes.nasdaq.com/asp/...ote.asp?symbol=GNBT&selected=GNBT  

Danke für dein Info.
Ich war der Meinung, dass der Kursanstieg der Info war, dass Generex weitere Zulassungen bekommen hat.
Dein Bericht #149

Gute Nacht an ALLE  

Ich glaub da war ich auf den richtigen Weg warum der Kursanstieg da war. Und mein Postig#150 war der Grund warum der Kurs nach Süden gefahren ist. Aber jetzt sollte es wieder nach Norden gehen.  

http://investor.generex.com/releasedetail.cfm?ReleaseID=389788  

http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7354336  

die 1 $ Marke testen, ob es darüber geht ???  

hatten wir bereits und danach ging es nur noch runter trotz guter Nachrichten. Es wurde auf Teufel komm raus abverkauft.  

http://www.transworldnews.com/NewsStory.aspx?id=100091&cat=8  

Source: Beacon Equity
Beacon Equity Issues Trading Outlook for Generex Biotechnology Corp.

DALLAS, July 27, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Generex Biotechnology Corp. (Nasdaq:GNBT). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The investment report on Generex Biotechnology Corp. (Nasdaq:GNBT) should be of particular interest to other pharmaceutical companies: CPEX Pharmaceuticals Inc. (Nasdaq:CPEX), Mannkind Corp. (Nasdaq:MNKD), Novo Nordisk A/S (NYSE:NVO), Life Technologies Corp. (Nasdaq:LIFE), King Pharmaceuticals (NYSE:KG) and Mylan Inc. (Nasdaq:MYL).

It is available at: http://www.beaconequity.com/i/GNBT

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Generex Biotechnology Corp. (GNBT) is a development-stage biopharmaceutical company engaged in research, development and commercialization of its proprietary platform technology for oral administration to treat metabolic and immunological diseases. The Company specializes in oral (buccal) cavity administration, using a hand-held aerosol applicator, of proteins, peptides, monoclonal antibodies, hormones and vaccines.

In the report, the analyst notes:

"The Company operates in an approximately $21 billion oral anti-diabetic market, which is growing at roughly 6% per year. Research company Visiongain predicts continued significant market growth as the population in the OECD countries median age climbs.

"On July 20, the Company announced the release of a study which demonstrates the results of a novel Ii-Key/HPV immunotherapeutic vaccine, details of which appear in the July 2009 edition of trade magazine, Vaccine. The study demonstrates an additional application of the Ii-Key technology platform, which is presently developed by the Company's solely owned subsidiary Antigen Express. Another peptide, AE37, of this application is currently in phase II trials for the treatment of breast cancer and phase I trials for the treatment of prostate cancer."

To read the entire report visit: http://www.beaconequity.com/i/GNBT

BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

[...]

http://www.globenewswire.com/newsroom/...ml?ref=rss&&d=169830  

Vor einer Woche ist einer der Gründer von AMGEN als technischer Direktor und Berater bei Generex eingestiegen. Generex erwartet demnächst den FDA Bescheid für Oral-Lyn (Behandlung Diabetes Type 1 und 2 ohne Spritzen, durch Mundzufuhr des Insulins) und auch charttechnisch ist momentan die Lage interressant. Momentan wird Generex Biotech (Ticker USA: GNBT) bei ca.61,5 US-Cents gehandelt, hat aber das Potential kurzfristig bis 1-1,2 Dollar und mittelfristig bis 6 Dollar.
Bin persönlich mit 20000 Aktien dabei.  

Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company?s products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and GlucoBreak, a fat-free glucose spray. Generex Biotechnology Corporation?s under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; and morphine and fentanyl products for breakthrough and postoperative pain. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S. The company was founded in 1983 and is based in Toronto, Canada.


This stock has huge potential. Oral-lyn, the insulin spray is going to revolutionize the insulin industry. No more needles. This is a former $25 stock and is only trading at 61 cents, that's a tremendous bargain. If everything goes to plan this stock is going to explode! The sky's the limit.

They took a big step in the right direction with the hiring of Dr. Joseph Rubinfeld as the Company's Chief Scientific Advisor. Rubinfeld was responsible for the development of the multi-billion dollar antibiotic Amoxicillin and has 50 years experience in the industry.

Amgen Co-founder to Act as Generex Chief Scientific Advisor (Nasdaq:GNBT)

This stock is definitely worth a look. I'm in a 48 cents and holding on for the ride.  

http://www.worldmarketmedia.com/856/section.aspx/...;Page=MEDIAVIEWER  

http://www.marketwatch.com/story/...l-swine-flu-conference-2009-08-27  

http://www.streetinsider.com/FDA/...+of+Generex+Oral-lyn/4933931.html  

http://www.marketwatch.com/story/...stered-direct-offering-2009-09-14  

http://www.boston.com/business/ticker/2009/09/generex_drug_is.html  

http://www.boerse-go.de/nachricht/...bei-Ausbruch-ueber,a1914411.html  

http://www.tradingmarkets.com/.site/news/Stock%20News/2579088/  

Wollte gerade auch beide News einsetzten. Schön das auch jemand anderes sich Mühe gibt.  

http://industry.bnet.com/pharma/10004745/...ompetitor-bashing-afresa/

Wie denkt ihr darüber......???

 

http://www.tradingmarkets.com/.site/news/Stock%20News/2587886/  

 

 

http://money.cnn.com/news/newsfeeds/articles/globenewswire/179533.htm

Gruß
Ganswindt

Generex Größe und Menge für ganz New York City !

3. Dezember 2009 (FinancialWire) Generex Biotechnology Corporation (NASDAQ: GNBT) (www.generex.com), ein führendes Unternehmen in den Bereichen Medikamentenapplikation für Stoffwechselkrankheiten durch die innere Auskleidung der Mundhöhle, bekannt, dass. die Firmen Proprietäre Crave NX-7 - Day Diet Hilfe Spray wird in Kürze in Duane Reades 256 Drogerien erhältlich in New York City.

Crave-NX 7-Tage-Diät-Hilfe Spray ist eine große Weinprobe orange-bezogene Formulierung, besprüht und in den Mund verabreicht, wissenschaftlich formuliert, um schnell das Verlangen den ganzen Tag Einhalt zu gebieten, spart wertvolle Kalorien. Das Produkt wurde klinisch getestet, hat 20 Portionen pro Flasche, mit nur zwei Kalorien pro Portion und Null Fett. Crave-NX ist ein brandneues Ernährung Beihilfen, die den Spray Crave Away beim Speichern Kalorien durch die Kontrolle der Nutzer süßen Zahn-und Junk-Heißhunger den ganzen Tag über, die bis zu speichern 1000 Kalorien pro Tag kann helfen können.

Über einen Zeitraum von einem Jahr und spart nur 250 Kalorien pro Tag summiert sich auf über 90.000 Kalorien oder 26 Pfund. Crave-NX ist ein Produkt, positioniert ist, um andere Diät Produkte und / oder Programmen, die zusätzlichen Umsatz für den Einzelhandel und eine neue Diät-Add-On-Lösung für den Verbraucher zu ergänzen.

http://trak.in/india/...lable-throughout-new-york-city/economy-37415/

Source: Generex Product Available Throughout New York City

Wow !! :-)